The role of hematopoietic cell transplantation as therapy for myelodysplasia

Best Practice and Research: Clinical Haematology

Volumn 24, Issue 4, 2011, Pages 541-547

  Appelbaum, Frederick R ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

chronic myelomonocytic leukemia; hematopoietic cell transplantation; IPPS; myelodysplastic syndrome

Indexed keywords

AZACITIDINE; BECLOMETASONE; URSODEOXYCHOLIC ACID;

AGE SPECIFIC CARE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD SMEAR; COMORBIDITY; CYTOGENETICS; DRUG RESPONSE; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HUMAN; LIVER TOXICITY; LUNG TOXICITY; MYELODYSPLASTIC SYNDROME; NEPHROTOXICITY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RECURRENCE RISK; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 82355183524     PISSN: 15216926     EISSN: 15321924     Source Type: Journal    
DOI: 10.1016/j.beha.2011.09.010     Document Type: Review

References (23)

1. American Society of Blooad and Marrow Transplantation The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes Biol Blood Marrow Transplant 14 2008 135 136
2. D.M. Oliansky, J.H. Antin, and J.M. Bennett The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review Biol Blood Marrow Transplant 15 2009 137 172
3. C.S. Cutler, S.J. Lee, and P. Greenberg A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome Blood 104 2004 579 585 (Pubitemid 38900045)
4. V. Runde, T. de Witte, and R. Arnold Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation Bone Marrow Transplant 21 1998 255 261 (Pubitemid 28052228)
5. P. Greenberg, C. Cox, and M.M. LeBeau International scoring system for evaluating prognosis in myelodysplastic syndromes [erratum appears in Blood 1998 Feb 1;91(3):1100] Blood 89 1997 2079 2088 (Pubitemid 27132124)
6. J.W. Vardiman, N.L. Harris, and R.D. Brunning The World health Organization (WHO) classification of the myeloid neoplasms (review) Blood 100 2002 2292 2302
7. L. Malcovati, M.G. Porta, and C. Pascutto Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making J Clin Oncol 23 2005 7594 7603 (Pubitemid 46291823)
8. E.P. Alessandrino, M.G. Della Porta, and A. Bacigalupo WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) Blood 112 2008 895 902
9. D. Haase, U. Germing, and J. Schanz New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients Blood 110 2007 4385 4395 (Pubitemid 351377805)
10. H. Kantarjian, S. O'Brien, and F. Ravandi Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System Cancer 113 2008 1351 1361
11. L. Malcovati, U. Germing, and A. Kuendgen Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes J Clin Oncol 25 2007 3503 3510 (Pubitemid 47315575)
12. P. Fenaux, G.J. Mufti, and E. Hellstrom-Lindberg Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study Lancet Oncol 10 2009 223 232
13. R. Itzykson, S. Thpot, and B. Quesnel Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine Blood 117 2011 403 411
14. E. Jabbour, G. Garcia-Manero, and J. Shan Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy Cancer 116 2010 3830 3834
15. T. Prebet, S.D. Gore, and B. Esterni Outcome of patients (pts) treated for myelodysplastic syndrome (MDS) and secondary acute myeloid leukemia (s AML) after azacitidine (AZA) failure Blood 116 2010 199 #443
16. T.A. Gooley, J.W. Chien, and S.A. Pergam Reduced mortality after allogeneic hematopoietic-cell transplantation N Engl J Med 363 2010 2091 2101
17. G. Borthakur, and E. Estey Therapy-related acute myelogenous leukemia and myelodysplastic syndrome Curr Oncol Rep 9 2007 373 377 (Pubitemid 47377068)
18. C.K. Chang, B.E. Storer, and B.L. Scott Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders Blood 110 2007 1379 1387 (Pubitemid 47281440)
19. M.R. Litzow, S. Tarima, and W.S. Perez Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia Blood 115 2010 1850 1857
20. U. Germing, C. Strupp, and S. Knipp Chronic myelomonocytic leukemia in the light of the WHO proposals Haematologica 92 2007 974 977 (Pubitemid 350144245)
21. H. Eissa, T.A. Gooley, and M.L. Sorror Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities Biol Blood Marrow Transplant 17 6 2011 908 915
22. J.E. Anderson, F.R. Appelbaum, and G. Schoch Allogeneic marrow transplantation for refractory anemia: a comparison of two preparative regimens and analysis of prognostic factors Blood 87 1996 51 58 (Pubitemid 26011819)
23. M.L. Sorror, B.M. Sandmaier, and B.E. Storer Comorbidity and disease status-based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation J Clin Oncol 25 27 2007 4246 4254 (Pubitemid 47554249)